Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.

Dutasteride may become the top choice for treating hair loss.

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review examines hormonal influences on acne development and available hormonal therapies but reports no new clinical results.

This review discusses the physiology and potential hormonal mechanisms involved in female pattern hair loss, as well as the current hormonal and hormone-modifying treatments available, but reports no new research findings.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.

This study reports that hormonal therapies, particularly combined oral contraceptives, are commonly used and effective in treating acne in women, especially those with hormonal imbalances or specific acne patterns, regardless of their serum androgen levels.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This article reviews the effects of various medications on male fertility, noting that while commonly used drugs can mostly have reversible impacts, conclusive human evidence remains limited.

This study found that despite the presence of steroidogenesis inhibitors, CRPC tumor cells adapt to continue synthesizing androgens, suggesting a need for more effective androgen axis targeting.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review discusses the impact of medical and surgical treatments for LUTS/BPH on ejaculatory function, highlighting that most treatments negatively affect it, except for some minimally invasive surgical therapies and specific medical therapies.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This review examines the skin manifestations associated with COVID-19 but reports no new clinical findings, emphasizing the need for differential diagnoses to correlate skin symptoms with the virus.

This study reports two distinct patterns of hair changes in postmenopausal women, linking diffuse generalized scalp hair loss to older age and frontal hair loss to higher facial hair scores and younger age.

This article reviews treatment options for androgenetic alopecia, highlighting potential uses of plant materials, but reports no new clinical results.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This article discusses topical pharmaceutical compositions with 5-alpha reductase inhibitors for treating androgenetic alopecia and reports no clinical results.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This research highlights the shift from surgical to pharmacologic and less invasive treatments for benign prostatic hyperplasia, noting finasteride's effectiveness in men with enlarged prostates and its ability to reduce acute urinary retention risk compared to alpha-blockers.

This study found that developmental changes in testosterone synthesis and gene regulation may explain age differences in corticosterone release in response to stress between adolescent and adult rats.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.